Codexis, Inc. (CDXS) 10-Year Financial Performance & Capital Metrics

CDXS • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutCodexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Show more

Revenue $59M -15.4%
EBITDA -$59M +6.2%
Net Income -$65M +14.4%
EPS (Diluted) -0.89 +20.5%
Gross Margin 72.55% -11.2%
EBITDA Margin -98.89% -10.9%
Operating Margin -98.61% -1.6%
Net Margin -109.99% -1.2%
ROE -85.03% -29.0%
ROIC -60.5% +33.6%
Debt/Equity 0.89 +383.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.33%

5Y-2.82%

3Y-17.26%

TTM-17.87%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-2.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM12.64%

ROCE

10Y Avg-32.22%

5Y Avg-27.85%

3Y Avg-37.89%

Latest-51.77%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	41.8M	48.84M	50.02M	60.59M	68.46M	69.06M	104.75M	138.59M	70.14M	59.34M
Revenue Growth %	0.18%	0.17%	0.02%	0.21%	0.13%	0.01%	0.52%	0.32%	-0.49%	-0.15%
Cost of Goods Sold+	6.59M	9.75M	14.33M	12.62M	15.63M	13.74M	22.21M	38.03M	12.81M	16.29M
COGS % of Revenue	0.16%	0.2%	0.29%	0.21%	0.23%	0.2%	0.21%	0.27%	0.18%	0.27%
Gross Profit+	35.22M	39.08M	35.7M	47.97M	52.83M	55.31M	82.55M	100.56M	57.33M	43.06M
Gross Margin %	0.84%	0.8%	0.71%	0.79%	0.77%	0.8%	0.79%	0.73%	0.82%	0.73%
Gross Profit Growth %	0.38%	0.11%	-0.09%	0.34%	0.1%	0.05%	0.49%	0.22%	-0.43%	-0.25%
Operating Expenses+	42.99M	47.65M	58.67M	59.27M	65.38M	79.23M	105.24M	135.44M	125.4M	101.58M
OpEx % of Revenue	1.03%	0.98%	1.17%	0.98%	0.95%	1.15%	1%	0.98%	1.79%	1.71%
Selling, General & Admin	22.32M	25.42M	29.01M	29.29M	31.5M	35.05M	49.32M	52.17M	53.25M	55.15M
SG&A % of Revenue	0.53%	0.52%	0.58%	0.48%	0.46%	0.51%	0.47%	0.38%	0.76%	0.93%
Research & Development	20.67M	22.23M	29.66M	29.98M	33.87M	44.19M	55.92M	80.1M	58.88M	46.26M
R&D % of Revenue	0.49%	0.46%	0.59%	0.49%	0.49%	0.64%	0.53%	0.58%	0.84%	0.78%
Other Operating Expenses	-168K	-94K	-92K	-291K	0	0	0	3.17M	13.27M	165K
Operating Income+	-7.77M	-8.56M	-22.97M	-11.29M	-12.55M	-23.92M	-22.7M	-34.88M	-68.07M	-58.52M
Operating Margin %	-0.19%	-0.18%	-0.46%	-0.19%	-0.18%	-0.35%	-0.22%	-0.25%	-0.97%	-0.99%
Operating Income Growth %	0.59%	-0.1%	-1.68%	0.51%	-0.11%	-0.91%	0.05%	-0.54%	-0.95%	0.14%
EBITDA+	-2.36M	-4.02M	-21.93M	-10.15M	-7.99M	-19.37M	-16.75M	-29.48M	-62.55M	-58.68M
EBITDA Margin %	-0.06%	-0.08%	-0.44%	-0.17%	-0.12%	-0.28%	-0.16%	-0.21%	-0.89%	-0.99%
EBITDA Growth %	0.81%	-0.7%	-4.46%	0.54%	0.21%	-1.42%	0.14%	-0.76%	-1.12%	0.06%
D&A (Non-Cash Add-back)	5.41M	4.55M	1.04M	1.15M	4.56M	4.55M	5.95M	5.4M	5.52M	-165K
EBIT	-7.77M	-8.56M	-22.97M	-11.29M	-12.55M	-23.92M	-22.7M	-31.71M	-54.8M	-58.35M
Net Interest Income+	19K	60K	147K	671K	1.29M	405K	459K	1.44M	4.17M	3.67M
Interest Income	19K	60K	147K	671K	1.29M	405K	459K	1.44M	4.17M	3.67M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-149K	-34K	55K	380K	631K	249K	1.61M	1.56M	-8.1M	-6.72M
Pretax Income+	-7.92M	-8.6M	-22.91M	-10.91M	-11.92M	-23.67M	-21.09M	-33.32M	-76.17M	-65.24M
Pretax Margin %	-0.19%	-0.18%	-0.46%	-0.18%	-0.17%	-0.34%	-0.2%	-0.24%	-1.09%	-1.1%
Income Tax+	-338K	-40K	81K	-37K	17K	339K	189K	276K	69K	34K
Effective Tax Rate %	0.96%	1%	1%	1%	1%	1.01%	1.01%	1.01%	1%	1%
Net Income+	-7.58M	-8.56M	-23M	-10.88M	-11.94M	-24.01M	-21.28M	-33.59M	-76.24M	-65.28M
Net Margin %	-0.18%	-0.18%	-0.46%	-0.18%	-0.17%	-0.35%	-0.2%	-0.24%	-1.09%	-1.1%
Net Income Growth %	0.6%	-0.13%	-1.69%	0.53%	-0.1%	-1.01%	0.11%	-0.58%	-1.27%	0.14%
Net Income (Continuing)	-7.58M	-8.56M	-23M	-10.88M	-11.94M	-24.01M	-21.28M	-33.59M	-76.24M	-65.28M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.19	-0.21	-0.50	-0.21	-0.21	-0.40	-0.33	-0.51	-1.12	-0.89
EPS Growth %	0.62%	-0.11%	-1.38%	0.58%	0%	-0.9%	0.17%	-0.55%	-1.2%	0.21%
EPS (Basic)	-0.19	-0.21	-0.50	-0.21	-0.21	-0.40	-0.33	-0.51	-1.12	-0.89
Diluted Shares Outstanding	39.44M	40.63M	46.23M	52.2M	56.52M	59.36M	64.57M	65.34M	68.13M	73.41M
Basic Shares Outstanding	39.44M	40.63M	46.23M	52.2M	56.52M	59.36M	64.57M	65.34M	68.13M	73.41M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	32.84M	27.23M	45.04M	67.2M	114.2M	184.42M	161.89M	162.89M	93.47M	98.77M
Cash & Short-Term Investments	23.27M	19.24M	31.22M	53.04M	90.5M	150.12M	116.8M	113.98M	65.12M	73.46M
Cash Only	23.27M	19.24M	31.22M	53.04M	90.5M	149.12M	116.8M	113.98M	65.12M	19.26M
Short-Term Investments	0	0	0	0	0	1M	0	0	0	54.19M
Accounts Receivable	7.33M	5.92M	11.8M	13.5M	20.16M	29.29M	37.65M	40.87M	19.93M	18.88M
Days Sales Outstanding	63.99	44.27	86.1	81.33	107.46	154.8	131.19	107.65	103.7	116.15
Inventory	992K	825K	1.04M	589K	371K	964K	1.16M	2.03M	2.69M	1.8M
Days Inventory Outstanding	54.98	30.88	26.39	17.04	8.66	25.6	19.06	19.47	76.51	40.31
Other Current Assets	1.25M	1.24M	984K	0	661K	638K	579K	521K	5.74M	4.63M
Total Non-Current Assets+	11.81M	8.42M	8.59M	11.09M	34.87M	37.22M	84.5M	87.5M	43.09M	50.24M
Property, Plant & Equipment	3.11M	2.15M	2.81M	4.76M	30.39M	31.18M	65.46M	61.88M	28.62M	42.9M
Fixed Asset Turnover	13.45x	22.66x	17.77x	12.73x	2.25x	2.22x	1.60x	2.24x	2.45x	1.38x
Goodwill	3.24M	3.24M	3.24M	3.24M	3.24M	3.24M	3.24M	3.24M	2.46M	2.46M
Intangible Assets	2.81M	0	0	0	0	0	0	0	0	0
Long-Term Investments	1.55M	1.14M	671K	588K	0	1.45M	14M	20.51M	9.7M	2.8M
Other Non-Current Assets	1.1M	1.88M	1.86M	2.5M	1.24M	1.36M	1.79M	1.87M	2.31M	2.08M
Total Assets+	44.65M	35.65M	53.63M	78.28M	149.07M	221.65M	246.38M	250.39M	136.56M	149.01M
Asset Turnover	0.94x	1.37x	0.93x	0.77x	0.46x	0.31x	0.43x	0.55x	0.51x	0.40x
Asset Growth %	-0.07%	-0.2%	0.5%	0.46%	0.9%	0.49%	0.11%	0.02%	-0.45%	0.09%
Total Current Liabilities+	14.84M	12.37M	24.95M	17.11M	15.39M	24.98M	33.37M	49.07M	35.83M	23.65M
Accounts Payable	3.4M	4.23M	3.54M	3.05M	2.62M	2.97M	3M	3.25M	5.95M	2.84M
Days Payables Outstanding	188.37	158.38	90.31	88.21	61.2	78.89	49.22	31.15	169.46	63.6
Short-Term Debt	-425K	-425K	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	57K	1000K	1000K	1000K	1000K	350K
Other Current Liabilities	1.06M	940K	4.36M	5.8M	5M	10.27M	11.12M	11.45M	11.25M	11.41M
Current Ratio	2.21x	2.20x	1.81x	3.93x	7.42x	7.38x	4.85x	3.32x	2.61x	4.18x
Quick Ratio	2.15x	2.13x	1.76x	3.89x	7.40x	7.34x	4.82x	3.28x	2.53x	4.10x
Cash Conversion Cycle	-69.41	-83.23	22.18	10.15	54.92	101.52	101.04	95.97	10.75	92.86
Total Non-Current Liabilities+	6.93M	4.18M	4.13M	4.86M	28.17M	26.56M	48.62M	56.53M	14.12M	58.44M
Long-Term Debt	0	0	0	0	0	0	0	0	0	28.91M
Capital Lease Obligations	0	0	302K	61K	24.95M	22.32M	43.56M	38.28M	12.24M	28.16M
Deferred Tax Liabilities	-1.31M	-885K	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.81M	3.12M	2.32M	1.45M	1.23M	1.27M	1.31M	1.37M	1.23M	1.27M
Total Liabilities	21.77M	16.55M	29.08M	21.98M	43.56M	51.54M	81.99M	105.6M	49.95M	82.08M
Total Debt+	425K	425K	302K	61K	26.12M	24.95M	47.65M	43.64M	16.02M	59.9M
Net Debt	-22.85M	-18.82M	-30.92M	-52.98M	-64.38M	-124.17M	-69.14M	-70.35M	-49.09M	40.63M
Debt / Equity	0.02x	0.02x	0.01x	0.00x	0.25x	0.15x	0.29x	0.30x	0.19x	0.89x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	22.88M	19.1M	24.55M	56.31M	105.52M	170.1M	164.39M	144.8M	86.61M	66.93M
Equity Growth %	-0.13%	-0.17%	0.29%	1.29%	0.87%	0.61%	-0.03%	-0.12%	-0.4%	-0.23%
Book Value per Share	0.58	0.47	0.53	1.08	1.87	2.87	2.55	2.22	1.27	0.91
Total Shareholders' Equity	22.88M	19.1M	24.55M	56.31M	105.52M	170.1M	164.39M	144.8M	86.61M	66.93M
Common Stock	4K	4K	5K	5K	6K	6K	6K	6K	7K	8K
Retained Earnings	-283.51M	-292.07M	-315.06M	-330.47M	-342.41M	-366.42M	-387.7M	-421.29M	-497.53M	-562.81M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	405K	0	-472K	0	0	0	0	0	0	52K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-433K	-2.7M	-8.76M	-14.09M	-12.56M	-16.46M	-14.27M	11.28M	-52.64M	-49.41M
Operating CF Margin %	-0.01%	-0.06%	-0.18%	-0.23%	-0.18%	-0.24%	-0.14%	0.08%	-0.75%	-0.83%
Operating CF Growth %	-2.35%	-5.24%	-2.24%	-0.61%	0.11%	-0.31%	0.13%	1.79%	-5.66%	0.06%
Net Income	-7.58M	-8.56M	-23M	-10.88M	-11.94M	-24.01M	-21.28M	-33.59M	-76.24M	-65.28M
Depreciation & Amortization	5.41M	4.55M	1.04M	1.15M	4.56M	4.55M	5.95M	10.25M	9.92M	4.95M
Stock-Based Compensation	5.13M	5.67M	7.09M	7.89M	6.94M	7.73M	11.59M	14.53M	9.97M	13.09M
Deferred Taxes	-314K	0	9K	0	0	-900K	-2.88M	0	0	0
Other Non-Cash Items	32K	-42K	-207K	91K	525K	55K	-19K	-1.48M	21.93M	9.85M
Working Capital Changes	-3.1M	-4.32M	6.3M	-12.34M	-12.65M	-3.89M	-7.62M	21.57M	-18.22M	-12.02M
Change in Receivables	-3.46M	1.41M	-5.65M	960K	2.52M	-12.32M	-15.57M	-3.23M	20.25M	1.25M
Change in Inventory	403K	167K	-210K	447K	217K	-593K	-196K	-869K	-656K	886K
Change in Payables	-1.27M	942K	-801K	-524K	-428K	101K	268K	207K	2.29M	-2.57M
Cash from Investing+	-1.26M	-842K	-908K	-2.77M	-3.67M	-5.75M	-21.42M	-13.58M	-4.86M	-56.98M
Capital Expenditures	-1.2M	-888K	-985K	-2.77M	-3.73M	-3.75M	-13.83M	-8.31M	-4.42M	-4.3M
CapEx % of Revenue	0.03%	0.02%	0.02%	0.05%	0.05%	0.05%	0.13%	0.06%	0.06%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-58K	46K	77K	2K	3K	0	36K	29K	-440K	0
Cash from Financing+	-1.52M	-490K	21.65M	38.57M	53.96M	80.81M	3.77M	-575K	8.17M	60.52M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.52M	-490K	-1.96M	1.31M	4.2M	-5.38M	-1.21M	-1.49M	-485K	-318K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.63M	-3.59M	-9.75M	-16.86M	-16.29M	-20.21M	-28.09M	2.98M	-57.06M	-53.72M
FCF Margin %	-0.04%	-0.07%	-0.19%	-0.28%	-0.24%	-0.29%	-0.27%	0.02%	-0.81%	-0.91%
FCF Growth %	-86.89%	-1.2%	-1.72%	-0.73%	0.03%	-0.24%	-0.39%	1.11%	-20.17%	0.06%
FCF per Share	-0.04	-0.09	-0.21	-0.32	-0.29	-0.34	-0.44	0.05	-0.84	-0.73
FCF Conversion (FCF/Net Income)	0.06x	0.32x	0.38x	1.30x	1.05x	0.69x	0.67x	-0.34x	0.69x	0.76x
Interest Paid	0	14K	141K	84K	49K	52K	14K	34K	44K	2.57M
Taxes Paid	8K	5K	32K	5K	5K	312K	102K	100K	194K	17K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-30.82%	-40.77%	-105.38%	-26.91%	-14.75%	-17.42%	-12.72%	-21.73%	-65.89%	-85.03%
Return on Invested Capital (ROIC)	-18798.39%	-4078.1%	-	-254.54%	-42.33%	-41.21%	-24.11%	-30.83%	-91.19%	-60.5%
Gross Margin	84.25%	80.03%	71.36%	79.17%	77.17%	80.1%	78.8%	72.56%	81.74%	72.55%
Net Margin	-18.13%	-17.52%	-45.97%	-17.95%	-17.43%	-34.77%	-20.31%	-24.24%	-108.69%	-109.99%
Debt / Equity	0.02x	0.02x	0.01x	0.00x	0.25x	0.15x	0.29x	0.30x	0.19x	0.89x
FCF Conversion	0.06x	0.32x	0.38x	1.30x	1.05x	0.69x	0.67x	-0.34x	0.69x	0.76x
Revenue Growth	18.4%	16.82%	2.43%	21.13%	12.98%	0.87%	51.69%	32.3%	-49.39%	-15.39%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	-	36.79M
Product Growth	-	-	-	-	-	-	-	-	-	-
Research and Development Revenue	-	-	-	2.73M	57K	2.3M	3.05M	1.61M	27.24M	22.56M
Research and Development Revenue Growth	-	-	-	-	-97.92%	3940.35%	32.61%	-47.18%	1588.59%	-17.18%
Sitagliptin Enzyme	-	-	-	-	-	-	2.8M	1.6M	-	2.5M
Sitagliptin Enzyme Growth	-	-	-	-	-	-	-	-42.86%	-	-
Enzyme Product	-	-	-	-	-	-	1.7M	75.4M	8.2M	-
Enzyme Product Growth	-	-	-	-	-	-	-	4335.29%	-89.12%	-
Product Sales	-	-	-	2.2M	1.99M	2.49M	3.28M	29M	-	-
Product Sales Growth	-	-	-	-	-9.72%	25.21%	31.87%	783.75%	-	-
Service	-	-	-	35M	38.99M	38.84M	34.1M	-	-	-
Service Growth	-	-	-	-	11.40%	-0.40%	-12.20%	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Asia Pacific	-	-	-	-	-	-	61.09M	65.05M	33.5M	27.71M
Asia Pacific Growth	-	-	-	-	-	-	-	6.49%	-48.50%	-17.30%
UNITED STATES	24.8M	21.31M	15.47M	-	-	-	-	-	13.7M	21.3M
UNITED STATES Growth	-	-14.06%	-27.41%	-	-	-	-	-	-	55.47%
Americas	-	-	-	15.37M	13.04M	24.35M	23.48M	17M	13.73M	21.28M
Americas Growth	-	-	-	-	-15.17%	86.76%	-3.58%	-27.60%	-19.22%	54.94%
EMEA	-	-	-	22.36M	37.13M	19.26M	20.19M	56.54M	22.91M	10.36M
EMEA Growth	-	-	-	-	66.06%	-48.14%	4.83%	180.08%	-59.49%	-54.78%
CHINA	-	-	-	-	-	-	-	-	20.3M	9.8M
CHINA Growth	-	-	-	-	-	-	-	-	-	-51.72%
INDIA	1.03M	3.58M	5.64M	-	-	-	-	-	-	7.3M
INDIA Growth	-	248.73%	57.60%	-	-	-	-	-	-	-
SINGAPORE	963K	3.84M	6.17M	-	-	-	-	-	-	6.2M
SINGAPORE Growth	-	298.34%	60.71%	-	-	-	-	-	-	-
SWITZERLAND	-	-	13.22M	-	-	-	-	-	11.1M	3.4M
SWITZERLAND Growth	-	-	-	-	-	-	-	-	-	-69.37%
IRELAND	-	-	-	-	-	-	-	-	500K	1.8M
IRELAND Growth	-	-	-	-	-	-	-	-	-	260.00%
APAC	-	-	-	22.86M	18.29M	25.45M	-	-	-	-
APAC Growth	-	-	-	-	-20.02%	39.16%	-	-	-	-
the World	-	-	9.48M	-	-	-	-	-	-	-
the World Growth	-	-	-	-	-	-	-	-	-	-
Europe	14.15M	17.14M	-	-	-	-	-	-	-	-
Europe Growth	-	21.11%	-	-	-	-	-	-	-	-
Others	5K	1.82M	-	-	-	-	-	-	-	-
Others Growth	-	36240.00%	-	-	-	-	-	-	-	-
Other Asian Countries	864K	1.16M	-	-	-	-	-	-	-	-
Other Asian Countries Growth	-	34.14%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Codexis, Inc. (CDXS) reported $52.9M in revenue for fiscal year 2024. This represents a 57% decrease from $123.9M in 2011.

Codexis, Inc. (CDXS) saw revenue decline by 15.4% over the past year.

Codexis, Inc. (CDXS) reported a net loss of $64.0M for fiscal year 2024.

Dividend & Returns

Codexis, Inc. (CDXS) has a return on equity (ROE) of -85.0%. Negative ROE indicates the company is unprofitable.

Codexis, Inc. (CDXS) had negative free cash flow of $61.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Codexis, Inc. (CDXS) 10-Year Financial Performance & Capital Metrics

CDXS • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $59M -15.4%
EBITDA -$59M +6.2%
Net Income -$65M +14.4%
EPS (Diluted) -0.89 +20.5%
Gross Margin 72.55% -11.2%
EBITDA Margin -98.89% -10.9%
Operating Margin -98.61% -1.6%
Net Margin -109.99% -1.2%
ROE -85.03% -29.0%
ROIC -60.5% +33.6%
Debt/Equity 0.89 +383.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.33%

5Y-2.82%

3Y-17.26%

TTM-17.87%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-2.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM12.64%

ROCE

10Y Avg-32.22%

5Y Avg-27.85%

3Y Avg-37.89%

Latest-51.77%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	41.8M	48.84M	50.02M	60.59M	68.46M	69.06M	104.75M	138.59M	70.14M	59.34M
Revenue Growth %	0.18%	0.17%	0.02%	0.21%	0.13%	0.01%	0.52%	0.32%	-0.49%	-0.15%
Cost of Goods Sold+	6.59M	9.75M	14.33M	12.62M	15.63M	13.74M	22.21M	38.03M	12.81M	16.29M
COGS % of Revenue	0.16%	0.2%	0.29%	0.21%	0.23%	0.2%	0.21%	0.27%	0.18%	0.27%
Gross Profit+	35.22M	39.08M	35.7M	47.97M	52.83M	55.31M	82.55M	100.56M	57.33M	43.06M
Gross Margin %	0.84%	0.8%	0.71%	0.79%	0.77%	0.8%	0.79%	0.73%	0.82%	0.73%
Gross Profit Growth %	0.38%	0.11%	-0.09%	0.34%	0.1%	0.05%	0.49%	0.22%	-0.43%	-0.25%
Operating Expenses+	42.99M	47.65M	58.67M	59.27M	65.38M	79.23M	105.24M	135.44M	125.4M	101.58M
OpEx % of Revenue	1.03%	0.98%	1.17%	0.98%	0.95%	1.15%	1%	0.98%	1.79%	1.71%
Selling, General & Admin	22.32M	25.42M	29.01M	29.29M	31.5M	35.05M	49.32M	52.17M	53.25M	55.15M
SG&A % of Revenue	0.53%	0.52%	0.58%	0.48%	0.46%	0.51%	0.47%	0.38%	0.76%	0.93%
Research & Development	20.67M	22.23M	29.66M	29.98M	33.87M	44.19M	55.92M	80.1M	58.88M	46.26M
R&D % of Revenue	0.49%	0.46%	0.59%	0.49%	0.49%	0.64%	0.53%	0.58%	0.84%	0.78%
Other Operating Expenses	-168K	-94K	-92K	-291K	0	0	0	3.17M	13.27M	165K
Operating Income+	-7.77M	-8.56M	-22.97M	-11.29M	-12.55M	-23.92M	-22.7M	-34.88M	-68.07M	-58.52M
Operating Margin %	-0.19%	-0.18%	-0.46%	-0.19%	-0.18%	-0.35%	-0.22%	-0.25%	-0.97%	-0.99%
Operating Income Growth %	0.59%	-0.1%	-1.68%	0.51%	-0.11%	-0.91%	0.05%	-0.54%	-0.95%	0.14%
EBITDA+	-2.36M	-4.02M	-21.93M	-10.15M	-7.99M	-19.37M	-16.75M	-29.48M	-62.55M	-58.68M
EBITDA Margin %	-0.06%	-0.08%	-0.44%	-0.17%	-0.12%	-0.28%	-0.16%	-0.21%	-0.89%	-0.99%
EBITDA Growth %	0.81%	-0.7%	-4.46%	0.54%	0.21%	-1.42%	0.14%	-0.76%	-1.12%	0.06%
D&A (Non-Cash Add-back)	5.41M	4.55M	1.04M	1.15M	4.56M	4.55M	5.95M	5.4M	5.52M	-165K
EBIT	-7.77M	-8.56M	-22.97M	-11.29M	-12.55M	-23.92M	-22.7M	-31.71M	-54.8M	-58.35M
Net Interest Income+	19K	60K	147K	671K	1.29M	405K	459K	1.44M	4.17M	3.67M
Interest Income	19K	60K	147K	671K	1.29M	405K	459K	1.44M	4.17M	3.67M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-149K	-34K	55K	380K	631K	249K	1.61M	1.56M	-8.1M	-6.72M
Pretax Income+	-7.92M	-8.6M	-22.91M	-10.91M	-11.92M	-23.67M	-21.09M	-33.32M	-76.17M	-65.24M
Pretax Margin %	-0.19%	-0.18%	-0.46%	-0.18%	-0.17%	-0.34%	-0.2%	-0.24%	-1.09%	-1.1%
Income Tax+	-338K	-40K	81K	-37K	17K	339K	189K	276K	69K	34K
Effective Tax Rate %	0.96%	1%	1%	1%	1%	1.01%	1.01%	1.01%	1%	1%
Net Income+	-7.58M	-8.56M	-23M	-10.88M	-11.94M	-24.01M	-21.28M	-33.59M	-76.24M	-65.28M
Net Margin %	-0.18%	-0.18%	-0.46%	-0.18%	-0.17%	-0.35%	-0.2%	-0.24%	-1.09%	-1.1%
Net Income Growth %	0.6%	-0.13%	-1.69%	0.53%	-0.1%	-1.01%	0.11%	-0.58%	-1.27%	0.14%
Net Income (Continuing)	-7.58M	-8.56M	-23M	-10.88M	-11.94M	-24.01M	-21.28M	-33.59M	-76.24M	-65.28M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.19	-0.21	-0.50	-0.21	-0.21	-0.40	-0.33	-0.51	-1.12	-0.89
EPS Growth %	0.62%	-0.11%	-1.38%	0.58%	0%	-0.9%	0.17%	-0.55%	-1.2%	0.21%
EPS (Basic)	-0.19	-0.21	-0.50	-0.21	-0.21	-0.40	-0.33	-0.51	-1.12	-0.89
Diluted Shares Outstanding	39.44M	40.63M	46.23M	52.2M	56.52M	59.36M	64.57M	65.34M	68.13M	73.41M
Basic Shares Outstanding	39.44M	40.63M	46.23M	52.2M	56.52M	59.36M	64.57M	65.34M	68.13M	73.41M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	32.84M	27.23M	45.04M	67.2M	114.2M	184.42M	161.89M	162.89M	93.47M	98.77M
Cash & Short-Term Investments	23.27M	19.24M	31.22M	53.04M	90.5M	150.12M	116.8M	113.98M	65.12M	73.46M
Cash Only	23.27M	19.24M	31.22M	53.04M	90.5M	149.12M	116.8M	113.98M	65.12M	19.26M
Short-Term Investments	0	0	0	0	0	1M	0	0	0	54.19M
Accounts Receivable	7.33M	5.92M	11.8M	13.5M	20.16M	29.29M	37.65M	40.87M	19.93M	18.88M
Days Sales Outstanding	63.99	44.27	86.1	81.33	107.46	154.8	131.19	107.65	103.7	116.15
Inventory	992K	825K	1.04M	589K	371K	964K	1.16M	2.03M	2.69M	1.8M
Days Inventory Outstanding	54.98	30.88	26.39	17.04	8.66	25.6	19.06	19.47	76.51	40.31
Other Current Assets	1.25M	1.24M	984K	0	661K	638K	579K	521K	5.74M	4.63M
Total Non-Current Assets+	11.81M	8.42M	8.59M	11.09M	34.87M	37.22M	84.5M	87.5M	43.09M	50.24M
Property, Plant & Equipment	3.11M	2.15M	2.81M	4.76M	30.39M	31.18M	65.46M	61.88M	28.62M	42.9M
Fixed Asset Turnover	13.45x	22.66x	17.77x	12.73x	2.25x	2.22x	1.60x	2.24x	2.45x	1.38x
Goodwill	3.24M	3.24M	3.24M	3.24M	3.24M	3.24M	3.24M	3.24M	2.46M	2.46M
Intangible Assets	2.81M	0	0	0	0	0	0	0	0	0
Long-Term Investments	1.55M	1.14M	671K	588K	0	1.45M	14M	20.51M	9.7M	2.8M
Other Non-Current Assets	1.1M	1.88M	1.86M	2.5M	1.24M	1.36M	1.79M	1.87M	2.31M	2.08M
Total Assets+	44.65M	35.65M	53.63M	78.28M	149.07M	221.65M	246.38M	250.39M	136.56M	149.01M
Asset Turnover	0.94x	1.37x	0.93x	0.77x	0.46x	0.31x	0.43x	0.55x	0.51x	0.40x
Asset Growth %	-0.07%	-0.2%	0.5%	0.46%	0.9%	0.49%	0.11%	0.02%	-0.45%	0.09%
Total Current Liabilities+	14.84M	12.37M	24.95M	17.11M	15.39M	24.98M	33.37M	49.07M	35.83M	23.65M
Accounts Payable	3.4M	4.23M	3.54M	3.05M	2.62M	2.97M	3M	3.25M	5.95M	2.84M
Days Payables Outstanding	188.37	158.38	90.31	88.21	61.2	78.89	49.22	31.15	169.46	63.6
Short-Term Debt	-425K	-425K	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	57K	1000K	1000K	1000K	1000K	350K
Other Current Liabilities	1.06M	940K	4.36M	5.8M	5M	10.27M	11.12M	11.45M	11.25M	11.41M
Current Ratio	2.21x	2.20x	1.81x	3.93x	7.42x	7.38x	4.85x	3.32x	2.61x	4.18x
Quick Ratio	2.15x	2.13x	1.76x	3.89x	7.40x	7.34x	4.82x	3.28x	2.53x	4.10x
Cash Conversion Cycle	-69.41	-83.23	22.18	10.15	54.92	101.52	101.04	95.97	10.75	92.86
Total Non-Current Liabilities+	6.93M	4.18M	4.13M	4.86M	28.17M	26.56M	48.62M	56.53M	14.12M	58.44M
Long-Term Debt	0	0	0	0	0	0	0	0	0	28.91M
Capital Lease Obligations	0	0	302K	61K	24.95M	22.32M	43.56M	38.28M	12.24M	28.16M
Deferred Tax Liabilities	-1.31M	-885K	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.81M	3.12M	2.32M	1.45M	1.23M	1.27M	1.31M	1.37M	1.23M	1.27M
Total Liabilities	21.77M	16.55M	29.08M	21.98M	43.56M	51.54M	81.99M	105.6M	49.95M	82.08M
Total Debt+	425K	425K	302K	61K	26.12M	24.95M	47.65M	43.64M	16.02M	59.9M
Net Debt	-22.85M	-18.82M	-30.92M	-52.98M	-64.38M	-124.17M	-69.14M	-70.35M	-49.09M	40.63M
Debt / Equity	0.02x	0.02x	0.01x	0.00x	0.25x	0.15x	0.29x	0.30x	0.19x	0.89x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	22.88M	19.1M	24.55M	56.31M	105.52M	170.1M	164.39M	144.8M	86.61M	66.93M
Equity Growth %	-0.13%	-0.17%	0.29%	1.29%	0.87%	0.61%	-0.03%	-0.12%	-0.4%	-0.23%
Book Value per Share	0.58	0.47	0.53	1.08	1.87	2.87	2.55	2.22	1.27	0.91
Total Shareholders' Equity	22.88M	19.1M	24.55M	56.31M	105.52M	170.1M	164.39M	144.8M	86.61M	66.93M
Common Stock	4K	4K	5K	5K	6K	6K	6K	6K	7K	8K
Retained Earnings	-283.51M	-292.07M	-315.06M	-330.47M	-342.41M	-366.42M	-387.7M	-421.29M	-497.53M	-562.81M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	405K	0	-472K	0	0	0	0	0	0	52K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-433K	-2.7M	-8.76M	-14.09M	-12.56M	-16.46M	-14.27M	11.28M	-52.64M	-49.41M
Operating CF Margin %	-0.01%	-0.06%	-0.18%	-0.23%	-0.18%	-0.24%	-0.14%	0.08%	-0.75%	-0.83%
Operating CF Growth %	-2.35%	-5.24%	-2.24%	-0.61%	0.11%	-0.31%	0.13%	1.79%	-5.66%	0.06%
Net Income	-7.58M	-8.56M	-23M	-10.88M	-11.94M	-24.01M	-21.28M	-33.59M	-76.24M	-65.28M
Depreciation & Amortization	5.41M	4.55M	1.04M	1.15M	4.56M	4.55M	5.95M	10.25M	9.92M	4.95M
Stock-Based Compensation	5.13M	5.67M	7.09M	7.89M	6.94M	7.73M	11.59M	14.53M	9.97M	13.09M
Deferred Taxes	-314K	0	9K	0	0	-900K	-2.88M	0	0	0
Other Non-Cash Items	32K	-42K	-207K	91K	525K	55K	-19K	-1.48M	21.93M	9.85M
Working Capital Changes	-3.1M	-4.32M	6.3M	-12.34M	-12.65M	-3.89M	-7.62M	21.57M	-18.22M	-12.02M
Change in Receivables	-3.46M	1.41M	-5.65M	960K	2.52M	-12.32M	-15.57M	-3.23M	20.25M	1.25M
Change in Inventory	403K	167K	-210K	447K	217K	-593K	-196K	-869K	-656K	886K
Change in Payables	-1.27M	942K	-801K	-524K	-428K	101K	268K	207K	2.29M	-2.57M
Cash from Investing+	-1.26M	-842K	-908K	-2.77M	-3.67M	-5.75M	-21.42M	-13.58M	-4.86M	-56.98M
Capital Expenditures	-1.2M	-888K	-985K	-2.77M	-3.73M	-3.75M	-13.83M	-8.31M	-4.42M	-4.3M
CapEx % of Revenue	0.03%	0.02%	0.02%	0.05%	0.05%	0.05%	0.13%	0.06%	0.06%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-58K	46K	77K	2K	3K	0	36K	29K	-440K	0
Cash from Financing+	-1.52M	-490K	21.65M	38.57M	53.96M	80.81M	3.77M	-575K	8.17M	60.52M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.52M	-490K	-1.96M	1.31M	4.2M	-5.38M	-1.21M	-1.49M	-485K	-318K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.63M	-3.59M	-9.75M	-16.86M	-16.29M	-20.21M	-28.09M	2.98M	-57.06M	-53.72M
FCF Margin %	-0.04%	-0.07%	-0.19%	-0.28%	-0.24%	-0.29%	-0.27%	0.02%	-0.81%	-0.91%
FCF Growth %	-86.89%	-1.2%	-1.72%	-0.73%	0.03%	-0.24%	-0.39%	1.11%	-20.17%	0.06%
FCF per Share	-0.04	-0.09	-0.21	-0.32	-0.29	-0.34	-0.44	0.05	-0.84	-0.73
FCF Conversion (FCF/Net Income)	0.06x	0.32x	0.38x	1.30x	1.05x	0.69x	0.67x	-0.34x	0.69x	0.76x
Interest Paid	0	14K	141K	84K	49K	52K	14K	34K	44K	2.57M
Taxes Paid	8K	5K	32K	5K	5K	312K	102K	100K	194K	17K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-30.82%	-40.77%	-105.38%	-26.91%	-14.75%	-17.42%	-12.72%	-21.73%	-65.89%	-85.03%
Return on Invested Capital (ROIC)	-18798.39%	-4078.1%	-	-254.54%	-42.33%	-41.21%	-24.11%	-30.83%	-91.19%	-60.5%
Gross Margin	84.25%	80.03%	71.36%	79.17%	77.17%	80.1%	78.8%	72.56%	81.74%	72.55%
Net Margin	-18.13%	-17.52%	-45.97%	-17.95%	-17.43%	-34.77%	-20.31%	-24.24%	-108.69%	-109.99%
Debt / Equity	0.02x	0.02x	0.01x	0.00x	0.25x	0.15x	0.29x	0.30x	0.19x	0.89x
FCF Conversion	0.06x	0.32x	0.38x	1.30x	1.05x	0.69x	0.67x	-0.34x	0.69x	0.76x
Revenue Growth	18.4%	16.82%	2.43%	21.13%	12.98%	0.87%	51.69%	32.3%	-49.39%	-15.39%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	-	36.79M
Product Growth	-	-	-	-	-	-	-	-	-	-
Research and Development Revenue	-	-	-	2.73M	57K	2.3M	3.05M	1.61M	27.24M	22.56M
Research and Development Revenue Growth	-	-	-	-	-97.92%	3940.35%	32.61%	-47.18%	1588.59%	-17.18%
Sitagliptin Enzyme	-	-	-	-	-	-	2.8M	1.6M	-	2.5M
Sitagliptin Enzyme Growth	-	-	-	-	-	-	-	-42.86%	-	-
Enzyme Product	-	-	-	-	-	-	1.7M	75.4M	8.2M	-
Enzyme Product Growth	-	-	-	-	-	-	-	4335.29%	-89.12%	-
Product Sales	-	-	-	2.2M	1.99M	2.49M	3.28M	29M	-	-
Product Sales Growth	-	-	-	-	-9.72%	25.21%	31.87%	783.75%	-	-
Service	-	-	-	35M	38.99M	38.84M	34.1M	-	-	-
Service Growth	-	-	-	-	11.40%	-0.40%	-12.20%	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Asia Pacific	-	-	-	-	-	-	61.09M	65.05M	33.5M	27.71M
Asia Pacific Growth	-	-	-	-	-	-	-	6.49%	-48.50%	-17.30%
UNITED STATES	24.8M	21.31M	15.47M	-	-	-	-	-	13.7M	21.3M
UNITED STATES Growth	-	-14.06%	-27.41%	-	-	-	-	-	-	55.47%
Americas	-	-	-	15.37M	13.04M	24.35M	23.48M	17M	13.73M	21.28M
Americas Growth	-	-	-	-	-15.17%	86.76%	-3.58%	-27.60%	-19.22%	54.94%
EMEA	-	-	-	22.36M	37.13M	19.26M	20.19M	56.54M	22.91M	10.36M
EMEA Growth	-	-	-	-	66.06%	-48.14%	4.83%	180.08%	-59.49%	-54.78%
CHINA	-	-	-	-	-	-	-	-	20.3M	9.8M
CHINA Growth	-	-	-	-	-	-	-	-	-	-51.72%
INDIA	1.03M	3.58M	5.64M	-	-	-	-	-	-	7.3M
INDIA Growth	-	248.73%	57.60%	-	-	-	-	-	-	-
SINGAPORE	963K	3.84M	6.17M	-	-	-	-	-	-	6.2M
SINGAPORE Growth	-	298.34%	60.71%	-	-	-	-	-	-	-
SWITZERLAND	-	-	13.22M	-	-	-	-	-	11.1M	3.4M
SWITZERLAND Growth	-	-	-	-	-	-	-	-	-	-69.37%
IRELAND	-	-	-	-	-	-	-	-	500K	1.8M
IRELAND Growth	-	-	-	-	-	-	-	-	-	260.00%
APAC	-	-	-	22.86M	18.29M	25.45M	-	-	-	-
APAC Growth	-	-	-	-	-20.02%	39.16%	-	-	-	-
the World	-	-	9.48M	-	-	-	-	-	-	-
the World Growth	-	-	-	-	-	-	-	-	-	-
Europe	14.15M	17.14M	-	-	-	-	-	-	-	-
Europe Growth	-	21.11%	-	-	-	-	-	-	-	-
Others	5K	1.82M	-	-	-	-	-	-	-	-
Others Growth	-	36240.00%	-	-	-	-	-	-	-	-
Other Asian Countries	864K	1.16M	-	-	-	-	-	-	-	-
Other Asian Countries Growth	-	34.14%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Codexis, Inc. (CDXS) reported $52.9M in revenue for fiscal year 2024. This represents a 57% decrease from $123.9M in 2011.

Codexis, Inc. (CDXS) saw revenue decline by 15.4% over the past year.

Codexis, Inc. (CDXS) reported a net loss of $64.0M for fiscal year 2024.

Dividend & Returns

Codexis, Inc. (CDXS) has a return on equity (ROE) of -85.0%. Negative ROE indicates the company is unprofitable.

Codexis, Inc. (CDXS) had negative free cash flow of $61.7M in fiscal year 2024, likely due to heavy capital investments.